The global vascular grafts market size was valued at USD 1.7 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7.0% from 2022 to 2030. Key factors driving the market growth include the increasing number of dialysis procedures and rising chronic kidney disease (CKD) cases globally. Worldwide, over 2 million people receive treatment for dialysis. Around 37 million people in the U.S. and 3 million people are estimated to suffer from CKD. Moreover, the prevalence of cardiovascular diseases, diabetes, and end-stage renal disease is also expected to drive the market. Cardiovascular disease (CVD) is the leading cause of death in the U.S. and according to the data published by World Health Organization, an estimated 17.9 million people died due to CVD in 2019.
Moreover, the rising healthcare expenditure, availability of reimbursement policies, and rising demand for products with technological advancements are expected to offer multiple opportunities for market growth during the forecast period. Technological advancement is fostering the development of next-generation tissue-engineered vascular grafts to treat various vasculopathies. This technique rationally addresses critical challenges like intimal hyperplasia, thrombosis, and constructive graft remodeling.
Also, with the increasing demand for minimally invasive procedures, the adoption of MIDCAB procedure has risen, as it is safe and has a low mortality rate. Also, it is compatible with aortic cross-clamp and cardiopulmonary bypass. Furthermore, the advancement in surgical procedures using coronary artery stent-grafts is anticipated to impel the demand for vascular grafts in upcoming years.
Post COVID Outlook
The market decreased by 1.9% from 2019 to 2020
The market is estimated to witness a y-o-y growth of approximately 6.1 % to 6.9% in the next 5 years
Postponement of elective procedures to control the spread of COVID-19 and increasing prioritization of treatment associated with COVID-19 significantly reduced the sales of vascular graft products.
The development of innovative products, increasing focus of healthcare facilities, and strategies to resume elective vascular surgical procedures are expected to foster the market growth post-COVID-19 outbreak.
The pandemic also affected operations, supply chains, product distribution, manufacturing, and other business activities of the market players globally, which, in turn, had a negative impact on the market growth.
The increasing prevalence of various health conditions and rising demand for minimally invasive procedures as compared to open procedures is anticipated to drive their adoption in upcoming years
The outbreak of COVID-19 had a negative impact on the vascular grafts market due to the disruption in operations, supply chains, distribution systems, etc. Also, with the intent of controlling the spread of coronavirus, many elective procedures were canceled or postponed. Also, the healthcare professionals were focusing on COVID-19 treatment which declined the number of other non-essential surgeries. This resulted in a decline in revenue. For instance, in 2020, the cardiac and vascular group of Medtronic plc’s witnessed a 9.0% decrease in revenue as compared to 2019.
The extensive use of prosthetic grafts such as electrospun polyurethane vascular grafts for complex vascular trauma as it reduces the risk of neointimal formation is expected to propel the market over the forecast period.
Furthermore, the market players focusing on the introduction of innovative products are adding fuel to the market growth. For instance, in September 2021, Terumo Aortic launched PANTHER - a global surgical graft study of knitted and woven surgical grafts. Also, strategies such as mergers & acquisitions, collaborations, and partnerships adopted by key players to expand and strengthen the market are propelling the growth.
In 2021, the endovascular stent-grafts product segment dominated the market with a share of 63.8%. The rising adoption of endovascular stent-grafts to treat aneurysms including thoracic aortic aneurysms is the major factor contributing to the market growth. However, these endovascular stents - grafts are specially used for the treatment of abdominal aortic aneurysm (AAA), thereby impelling the growth.
Also, the mycotic aneurysm can be treated using these stent-grafts in combination with antibiotics. Moreover, a shift towards EVAR rather than conventional open thoracic aorta surgeries and technical development of endovascular application is expected to raise the demand for endovascular stent-grafts. Furthermore, the endovascular grafts help to recover fast and are less painful when compared to open surgeries of the chest. Also, it results in reduced hospital stays, thereby increasing its adoption.
However, the peripheral vascular grafts segment is expected to witness the fastest growth during the forecast period owing to the rising rate of renal failure and hardening of arteries. In addition, technological advancement in the development of products to treat peripheral artery disease is expected to impel the segment growth over a forecast period.
In 2021, the cardiac aneurysm segment held the largest market share of 51.9% owing to the rising prevalence of high blood pressure, rising cholesterol levels, sedentary lifestyle, and growing geriatric population. Also, congenital heart surgeries carried out using advanced tissue-engineered grafts are fostering segment growth. Moreover, the increasing incidences of organ transplant failure and surgical reconstruction for cardiovascular diseases have raised the adoption of minimally invasive vascular implants, thereby boosting the demand for cardiac aneurysm products.
The vascular occlusion segment is expected to witness the fastest growth during the forecast period owing to the increasing number of patients with vascular occlusion disease and the availability of procedures using grafts. Also, the treatment of vascular occlusion using synthetic grafts such as polytetrafluoroethylene (PTFE), is expected to impel market growth during the forecast period
The Polytetrafluoroethylene segment held the market revenue share of 46.4% in 2021 owing to its advantages such as high patency rates, high-pressure tolerance, etc. Also, it adequately interacts with the tissue and is easy to use. Therefore, they are extensively used for peripheral bypass procedures and extra-anatomical surgeries. Moreover, technological modifications such as PTFE treated with argon plasma for the development of innovative products are expected to boost the segment growth.
The polyester vascular graft segment is anticipated to register significant growth owing to the availability of raw materials and advantages such as durability and robustness. For instance, AbloGraft, and Polyester Vascular Graft offered by LeMaitre, are knitted and woven grafts that allow for deep penetration of bovine skin collagen and are manufactured with advanced sealant technology.
Moreover, due to the rise in the number of patients with vascular heart disease, the demand for functional polyester vascular grafts with small diameters has greatly increased, thereby positively impacting the segment growth.
North America held the largest market share of 30.2% in 2021 owing to the rising health awareness and availability of health care facilities for cardiovascular treatment in the region. Also, the availability of reimbursement policies and the adoption of advanced technological procedures are impelling the market growth.
Furthermore, the use of biometric tools to accurately diagnose the disease and technological developments and discoveries of tissue-engineered products are impelling the growth of biomaterials vascular grafts. Furthermore, the ongoing R&D for the development of grafts using advanced biomaterial is expected to drive the market over a forecast period.
However, Asia Pacific is expected to register the fastest growth during the forecast period. The region is heavily burdened by the increasing number of patients with cardiovascular diseases. Moreover, the population suffering from chronic kidney problems, end-stage heart disease, diabetes, etc. is anticipated to fuel market growth. In addition, the cardiac disorders leading to premature deaths are anticipated to foster market growth.
Partnerships, collaborations, mergers & acquisitions, and the development of new products are the key strategies adopted by key players operating in the market to gain a competitive edge in the market. For instance, in November 2019, Terumo Corporation announced the acquisition of Aortic Corporation. The acquisition aided the growth of the company’s vascular grafts business segment and contributed toward personalized aortic therapy.
Also, in December 2017, BD announced the acquisition of C. R. Bard, Inc. It aimed to build the company's leadership in infection prevention and medication management with an expanded solutions portfolio across the care continuum and enhance growth opportunities outside the U.S. market. Some of the prominent players operating in the vascular grafts market include:
LeMaitre Vascular, Inc.
W. L. Gore and Associates, Inc.
C. R. Bard
Shanghai Suokang Medical Implants Co. Ltd.
Market size value in 2022
USD 1.8 billion
Revenue forecast in 2030
USD 3.1 billion
CAGR of 7.0% from 2022 to 2030
Base year for estimation
2016 - 2020
2022 - 2030
Revenue in USD million, and CAGR from 2022 to 2030
Revenue, company ranking, competitive landscape, growth factors, and trends
Product, application, raw material, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Russia; Japan; China, India; Australia; Singapore; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE
Key companies profiled
Medtronic plc; Terumo Corporation; LeMaitre Vascular, Inc.; Getinge AB; Cook; C.R. Bard; W.L. Gore and Associates, Inc.; Shanghai Suokang Medical Implants Co. Ltd.
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research, Inc. has segmented the global vascular grafts market report based on product, application, raw material, and region:
Product Outlook (Revenue, USD Million, 2016 - 2030)
Hemodialysis Access Grafts
Endovascular Stent Grafts
Coronary Artery By-Pass Grafts
Vascular Grafts for Aorta Disease
Peripheral Vascular Grafts
Application Outlook (Revenue, USD Million, 2016 - 2030)
Endovascular Stent Graft
Coronary Artery Disease
Raw Material Outlook (Revenue, USD Million, 2016 - 2030)
Polyester Vascular Grafts
Polytetrafluoroethylene Vascular Grafts
Polyurethane Vascular Grafts
Biological Material Based Vascular Grafts
Human Saphenous and Umbilical Veins
Tissue Engineered Materials
Regional Outlook (Revenue, USD Million, 2016 - 2030)
b. The global vascular grafts market size was estimated at USD 1.7 billion in 2021 and is expected to reach USD 1.8 billion in 2022.
b. The global vascular grafts market is expected to grow at a compound annual growth rate of 7.0% from 2022 to 2030 to reach USD 3.1 billion by 2030.
b. Endovascular stent graft dominated the vascular grafts market with a share of 63.8% in 2020. This is attributable to the increasing number of abdominal aortic aneurysm procedures with less potential for access site complications.
b. Some key players operating in the vascular grafts market include Medtronic, plc; LeMaitre Vascular Inc.; Terumo Corp.; Getinge AB; W.L. Gore and Associates, Inc.; and Cook Medical, Inc.
b. Key factors that are driving the vascular grafts market growth include increasing incidence of cardiac diseases, diabetes, End-Stage Renal Disease (ESRD), and vascular occlusions.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."